| |
Article Title |
Author(s) |
Type (Status) |
Available Online |
|
Stop and go strategy for opioid switching requires flexibility
DOI: 10.1016/j.ejca.2011.11.039
I read with interest the paper published by Moksnes et al. This is the first controlled trial regarding opioid switching and authors should be complimented for giving such evidence-based information. ...
|
Sebastiano Mercadante
|
Correspondence
(In Press Corrected Proof)
|
06 February 2012 |
|
Identification of Familial Adenomatous Polyposis carriers among children with desmoid tumours
DOI: 10.1016/j.ejca.2012.01.004
Abstract: Objective: Desmoid tumours are rare mesenchymal tumours with unpredictable progression and high recurrence risk. They can occur sporadically or in association with Familial Adenomatous Polyp...
|
Anna A. Kattentidt-Mouravieva,
Ina R.R. Geurts-Giele,
Ronald R. de Krijger,
Max M. van Noesel,
Cees P. van de Ven,
Ans M.W. van den Ouweland,
Joan N.R. Kromosoeto,
Winand N.M. Dinjens,
Hendrikus J. Dubbink,
Ron Smits,
Anja Wagner
et al.
|
Full-length article
(In Press Corrected Proof)
|
06 February 2012 |
|
Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer
DOI: 10.1016/j.ejca.2012.01.007
Abstract: Background: The immunoglobulin G1 (IgG1) monoclonal antibody (MoAb) Cetuximab is active in metastatic colorectal cancer (mCRC) as first or subsequent lines of therapy. Efficacy seems restric...
|
Javier Rodríguez,
Ruth Zarate,
Eva Bandres,
Valentina Boni,
Amaia Hernández,
Jesus Javier Sola,
Beatriz Honorato,
Nerea Bitarte,
Jesus García-Foncillas
et al.
|
Full-length article
(In Press Corrected Proof)
|
06 February 2012 |
|
Treatment strategies for patients with stage IV rectal cancer: A report from the Swedish Rectal Cancer Registry
DOI: 10.1016/j.ejca.2011.12.012
Abstract: Background: The optimal treatment strategy for patients with stage IV rectal cancer is unclear. The aim of the present study was to describe trends and compare the different treatment strate...
|
M. Hosseinali Khani,
L. Påhlman,
K. Smedh
|
Full-length article
(In Press Corrected Proof)
|
06 February 2012 |
|
Reply to Professor Mercadante: Stop and go strategy for opioid switching requires flexibility
DOI: 10.1016/j.ejca.2011.12.033
To the Editor: We are grateful for the interest and response from Mercadante. This study was a randomized, phase II study, and we agree that there were obvious limitations, as discussed in the article...
|
Kristin Moksnes
|
Correspondence
(In Press Corrected Proof)
|
03 February 2012 |
|
Is the prognosis of stage 4s neuroblastoma in patients 12 months of age and older really excellent?
DOI: 10.1016/j.ejca.2012.01.010
Abstract: Purpose: In the International Neuroblastoma Risk Group (INRG) classification system, stage 4s was changed into stage MS in children less than 18months of age. Stage MS is defined as a metast...
|
Tomoko Iehara,
Eiso Hiyama,
Tatsuro Tajiri,
Akihiro Yoneda,
Minoru Hamazaki,
Masahiro Fukuzawa,
Hajime Hosoi,
Tohru Sugimoto,
Tadashi Sawada
et al.
|
Full-length article
(In Press Corrected Proof)
|
03 February 2012 |
|
ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality
DOI: 10.1016/j.ejca.2012.01.001
Abstract: Background: ERG (ETSregulated gene) protein expression has been shown to reflect ERG genomic rearrangements in prostate cancer (PCA). However, ERG protein expression prognostic value has not...
|
Tarek A. Bismar,
Michael Dolph,
Liang-Hong Teng,
Shuhong Liu,
Bryan Donnelly
et al.
|
Full-length article
(In Press Corrected Proof)
|
03 February 2012 |
|
Risk of haemorrhagic and ischaemic stroke in patients with cancer: A nationwide follow-up study from Sweden
DOI: 10.1016/j.ejca.2012.01.005
Abstract: Background: Stroke is common in cancer patients, but risk estimates for different cancer sites/types have not been determined. The aim of this nationwide study was to examine whether there i...
|
Bengt Zöller,
Jianguang Ji,
Jan Sundquist,
Kristina Sundquist
|
Full-length article
(In Press Corrected Proof)
|
01 February 2012 |
|
Sham-controlled, randomised, feasibility trial of acupuncture for prevention of radiation-induced xerostomia among patients with nasopharyngeal carcinoma
DOI: 10.1016/j.ejca.2011.12.030
Abstract: Background: Xerostomia (dry mouth) after head/neck radiation is a common problem among cancer patients. Quality of life (QOL) is impaired, and available treatments are of little benefit. Thi...
|
Zhiqiang Meng,
M. Kay Garcia,
Chaosu Hu,
Joseph Chiang,
Mark Chambers,
David I. Rosenthal,
Huiting Peng,
Caijun Wu,
Qi Zhao,
Genming Zhao,
Luming Liu,
Amy Spelman,
J. Lynn Palmer,
Qi Wei,
Lorenzo Cohen
et al.
|
Full-length article
(In Press Corrected Proof)
|
30 January 2012 |
|
Predictors of prescription errors involving anticancer chemotherapy agents
DOI: 10.1016/j.ejca.2011.12.031
Abstract: Aim: The majority of medication errors that harm patients relate to the prescribing process. Our study aimed to identify the predictors of prescription errors involving anticancer chemothera...
|
Florence Ranchon,
Céline Moch,
Benoît You,
Gilles Salles,
Vérane Schwiertz,
Nicolas Vantard,
Emilie Franchon,
Claude Dussart,
Emilie Henin,
Olivier Colomban,
Pascal Girard,
Gilles Freyer,
Catherine Rioufol
et al.
|
Full-length article
(In Press Corrected Proof)
|
30 January 2012 |
|
Rapamycin blocks hepatoblastoma growth in vitro and in vivo implicating new treatment options in high-risk patients
DOI: 10.1016/j.ejca.2011.12.032
Abstract: Activation of the protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signalling pathway plays a central role in the formation of hepatoblastoma (HB), the most common liver cancer in...
|
Ferdinand Wagner,
Bente Henningsen,
Christine Lederer,
Melanie Eichenmüller,
Jan Gödeke,
Josef Müller-Höcker,
Dietrich von Schweinitz,
Roland Kappler
et al.
|
Full-length article
(In Press Corrected Proof)
|
30 January 2012 |
|
Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours
DOI: 10.1016/j.ejca.2011.12.026
Abstract: Aim: The safety, pharmacokinetics and efficacy of sorafenib plus docetaxel in patients with advanced refractory cancer were investigated in a Phase I, dose-escalation trial. Methods: Twenty-...
|
Ahmad Awada,
Alain Hendlisz,
Olaf Christensen,
Chetan D. Lathia,
Sylvie Bartholomeus,
Fabienne Lebrun,
Dominique de Valeriola,
Erich Brendel,
Martin Radtke,
Thierry Delaunoit,
Martine Piccart-Gebhart,
Thierry Gil
et al.
|
Full-length article
(In Press Corrected Proof)
|
30 January 2012 |
|
Cediranib monotherapy in patients with advanced renal cell carcinoma: Results of a randomised phase II study
DOI: 10.1016/j.ejca.2011.12.022
Abstract: Background: Cediranib is a highly potent vascular endothelial growth factor (VEGF) signalling inhibitor with activity against VEGF receptors 1, 2 and 3. This Phase II, randomised, double-bli...
|
Peter Mulders,
Robert Hawkins,
Paul Nathan,
Igle de Jong,
Susanne Osanto,
Emilio Porfiri,
Andrew Protheroe,
Carla M.L. van Herpen,
Bijoyesh Mookerjee,
Laura Pike,
Juliane M. Jürgensmeier,
Martin E. Gore
et al.
|
Full-length article
(In Press Corrected Proof)
|
30 January 2012 |
|
Adaptive designs at European Organisation for Research and Treatment of Cancer (EORTC) with a focus on adaptive sample size re-estimation based on interim-effect size
DOI: 10.1016/j.ejca.2011.12.024
Abstract: Given the high failure rates and the increased costs of Phase III trials in oncology and the recent explosion of targeted agents, researchers are looking for better design strategies to try ...
|
M. Mauer,
L. Collette,
J. Bogaerts,
European Organisation for Research and Treatment of Cancer (EORTC) Statistics Department
|
Full-length article
(In Press Corrected Proof)
|
27 January 2012 |
|
Inhibition of human hepatocellular carcinoma HepG2 by phthalocyanine photosensitiser ZnPcS2P2: ROS production, apoptosis, cell cycle arrest
DOI: 10.1016/j.ejca.2011.10.013
Abstract: Photodynamic therapy (PDT) has been accepted as an alternative treatment for cancer. The rationale for the development of PDT for cancer is that target specificity can be achieved by control...
|
Jingwei Shao,
Jinping Xue,
Yongchao Dai,
Hong Liu,
Lee Jia,
Naisheng Chen,
Jinling Huang
et al.
|
Full-length article
(In Press Corrected Proof)
|
24 January 2012 |
|
Quantifying heterogeneity in human tumours using MRI and PET
DOI: 10.1016/j.ejca.2011.12.025
Abstract: Most tumours, even those of the same histological type and grade, demonstrate considerable biological heterogeneity. Variations in genomic subtype, growth factor expression and local microen...
|
Marie-Claude Asselin,
James P.B. O’Connor,
Ronald Boellaard,
Neil A. Thacker,
Alan Jackson
et al.
|
Full-length article
(In Press Corrected Proof)
|
24 January 2012 |
|
Radiomics: Extracting more information from medical images using advanced feature analysis
DOI: 10.1016/j.ejca.2011.11.036
Abstract: Solid cancers are spatially and temporally heterogeneous. This limits the use of invasive biopsy based molecular assays but gives huge potential for medical imaging, which has the ability to...
|
Philippe Lambin,
Emmanuel Rios-Velazquez,
Ralph Leijenaar,
Sara Carvalho,
Ruud G.P.M. van Stiphout,
Patrick Granton,
Catharina M.L. Zegers,
Robert Gillies,
Ronald Boellard,
André Dekker,
Hugo J.W.L. Aerts
et al.
|
Full-length article
(In Press Corrected Proof)
|
18 January 2012 |
|
The antitumour activities induced by pegylated liposomal cytochalasin D in murine models
DOI: 10.1016/j.ejca.2011.12.018
Abstract: Cytochalasin D targets actin and is ubiquitous in eukaryotic cells. When cytochalasin D is used as a cytotoxic agent in cancer therapy, it causes significant side effects. To prevent this, c...
|
Feng-ying Huang,
Wen-li Mei,
Yue-nan Li,
Guang-hong Tan,
Hao-fu Dai,
Jun-li Guo,
Hua Wang,
Yong-hao Huang,
Huan-ge Zhao,
Song-lin Zhou,
Ling Li,
Ying-ying Lin
et al.
|
Full-length article
(In Press Corrected Proof)
|
18 January 2012 |
|
Combining capecitabine and bevacizumab in metastatic breast cancer: A comprehensive review
DOI: 10.1016/j.ejca.2011.12.007
Abstract: Both capecitabine and bevacizumab are established agents in the treatment of metastatic breast cancer, but until recently clinical data supporting their use in combination were limited. We r...
|
David Miles,
Christoph Zielinski,
Miguel Martin,
Eduard Vrdoljak,
Nicholas Robert
et al.
|
Full-length article
(In Press Corrected Proof)
|
18 January 2012 |
|
Effect of cigarette smoking on quality of life in small cell lung cancer patients
DOI: 10.1016/j.ejca.2011.12.002
Abstract: Background: Continued cigarette smoking after small cell lung cancer (SCLC) diagnosis has been shown to shorten patients’ survival, but little is known about the impact of smoking and cessat...
|
Jun Chen,
Yingwei Qi,
Jason A. Wampfler,
Aminah Jatoi,
Yolanda I. Garces,
Allan J. Busta,
Sumithra J. Mandrekar,
Ping Yang
et al.
|
Full-length article
(In Press Corrected Proof)
|
16 January 2012 |
|
A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression
DOI: 10.1016/j.ejca.2011.12.020
Abstract: Oncolytic viruses engineered to replicate in tumour cells but not in normal cells could be used as tumour-specific vectors carrying the therapeutic genes. We previously developed a telomeras...
|
Yasumoto Yamasaki,
Hiroshi Tazawa,
Yuuri Hashimoto,
Toru Kojima,
Shinji Kuroda,
Shuya Yano,
Ryosuke Yoshida,
Futoshi Uno,
Hiroyuki Mizuguchi,
Akira Ohtsuru,
Yasuo Urata,
Shunsuke Kagawa,
Toshiyoshi Fujiwara
et al.
|
Full-length article
(In Press Corrected Proof)
|
16 January 2012 |
|
A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma
DOI: 10.1016/j.ejca.2011.12.015
Abstract: Background: Osteosarcoma is the most common primary malignant tumour in young adults. An effective treatment strategy for relapsed patients is still not defined. Pemetrexed is a multitargete...
|
Florence Duffaud,
Gerlinde Egerer,
Stefano Ferrari,
Hisham Rassam,
Ulrike Boecker,
B. Bui-Nguyen
et al.
|
Full-length article
(In Press Corrected Proof)
|
16 January 2012 |
|
A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study)
DOI: 10.1016/j.ejca.2011.12.016
Abstract: Aim: To evaluate in a multicentre randomised study the effect on duration of febrile neutropenia (FN), the safety and cost-effectiveness of a single subcutaneous pegfilgrastim injection comp...
|
C. Sebban,
A. Lefranc,
L. Perrier,
P. Moreau,
D. Espinouse,
A. Schmidt,
L. Kammoun,
H. Ghesquieres,
C. Ferlay,
J.O. Bay,
S. Lissandre,
D. Pérol,
M. Michallet,
P. Quittet
et al.
|
Full-length article
(In Press Corrected Proof)
|
16 January 2012 |
|
Simultaneous inhibition of Src and Aurora kinases by SU6656 induces therapeutic synergy in human synovial sarcoma growth, invasion and angiogenesis in vivo
DOI: 10.1016/j.ejca.2011.12.028
Abstract: Synovial sarcoma is an obstinate, high-grade malignancy because of its modest responses to radiotherapy and chemotherapy; the identification of effective therapeutics for this sarcoma is the...
|
Ryuta Arai,
Masumi Tsuda,
Takuya Watanabe,
Toyoyuki Ose,
Chikashi Obuse,
Katsumi Maenaka,
Akio Minami,
Yusuke Ohba
et al.
|
Full-length article
(In Press Corrected Proof)
|
16 January 2012 |
|
A randomized phase II trial of S-1-oxaliplatin versus capecitabine–oxaliplatin in advanced gastric cancer
DOI: 10.1016/j.ejca.2011.12.017
Abstract: Purpose: S-1 or capecitabine plus oxaliplatin are considered active and tolerable in gastric cancer patients. We conducted a randomized phase II trial in gastric cancer patients to compare t...
|
Gun Min Kim,
Hei-Cheul Jeung,
Sun Young Rha,
Hyo Song Kim,
Inkyung Jung,
Byung Ho Nam,
Kyung Hee Lee,
Hyun Cheol Chung
et al.
|
Full-length article
(In Press Corrected Proof)
|
16 January 2012 |
|
Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer
DOI: 10.1016/j.ejca.2011.12.005
Abstract: Background: The purpose of this phase II trial was to evaluate the efficacy and safety of cetuximab and irinotecan as second-line treatment in patients with gastro-oesophageal adenocarcinoma...
|
K.R. Schønnemann,
M. Yilmaz,
J.K. Bjerregaard,
K.M. Nielsen,
P. Pfeiffer
et al.
|
Full-length article
(In Press Corrected Proof)
|
16 January 2012 |
|
Primary treatment and prognostic factors of small cell neuroendocrine carcinoma of the uterine cervix: A Taiwanese Gynecologic Oncology Group study
DOI: 10.1016/j.ejca.2011.12.014
Abstract: Background: Our aims were to investigate the treatment and clinicopathological variables in relation to prognosis in small cell neuroendocrine cervical carcinoma (SCNECC). Patients and metho...
|
Kung-Liahng Wang,
Ting-Chang Chang,
Shih-Ming Jung,
Chi-Hau Chen,
Ya-Min Cheng,
Hua-Hsi Wu,
Wen-Shiung Liou,
Shih-Tien Hsu,
Yu-Che Ou,
Lian-Shung Yeh,
Hung-Cheng Lai,
Chia-Yen Huang,
Tze-Chien Chen,
Chee-Jen Chang,
Chyong-Huey Lai
et al.
|
Full-length article
(In Press Corrected Proof)
|
16 January 2012 |
|
A DNA methylation signature associated with aberrant promoter DNA hypermethylation of DNMT3B in human colorectal cancer
DOI: 10.1016/j.ejca.2011.12.019
Abstract: Altered promoter DNA methylation, one of the most important molecular alterations in cancer, is proposed to correlate with deregulation of DNA methyltransferases, although the molecular mech...
|
Covadonga Huidobro,
Rocío G. Urdinguio,
Ramón María Rodríguez,
Cristina Mangas,
Vincenzo Calvanese,
Pablo Martínez-Camblor,
Cecilia Ferrero,
Adolfo Parra-Blanco,
Luis Rodrigo,
Álvaro J. Obaya,
Laura Suárez-Fernández,
Aurora Astudillo,
Henar Hernando,
Esteban Ballestar,
Agustín F. Fernández,
Mario F. Fraga
et al.
|
Full-length article
(In Press Corrected Proof)
|
16 January 2012 |
|
Prognostic stratification for children with hepatoblastoma: The SIOPEL experience
DOI: 10.1016/j.ejca.2011.12.011
Abstract: Purpose: To identify factors relevant to long-term outcome in newly diagnosed hepatoblastoma, and define subgroups for clinical research on tailoring treatment to the individual patient. Pat...
|
Rudolf Maibach,
Derek Roebuck,
Laurence Brugieres,
Michael Capra,
Penelope Brock,
Patrizia Dall’Igna,
Jean-Bernard Otte,
Beatriz De Camargo,
Jozsef Zsiros,
Arthur Zimmermann,
Daniel Aronson,
Margaret Childs,
Marcelo Scopinaro,
Bruce Morland,
Jack Plaschkes,
Piotr Czauderna,
Giorgio Perilongo
et al.
|
Full-length article
(In Press Corrected Proof)
|
16 January 2012 |
|
Trucut biopsy of breast lesions: The first step toward international standards in developing countries
DOI: 10.1016/j.ejca.2011.11.038
Abstract: The new concept in breast cancer diagnosis and treatment is based on a less invasive, more accurate and effective strategy, with a multidisciplinary approach in a specialised breast unit. Wh...
|
A. Joulaee,
M. Kalantari,
M. Kadivar,
S. Joulaee,
N. Bahrani,
M. Mangual,
Sh. Hosseini,
Gh. Etemadmoghadam
et al.
|
Full-length article
(In Press Corrected Proof)
|
16 January 2012 |
|
First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind study
DOI: 10.1016/j.ejca.2011.12.008
Abstract: Background: Conatumumab is a fully human monoclonal agonist antibody that binds to death receptor 5 and induces apoptosis in sensitive cells. This study evaluated the safety and efficacy of ...
|
George D. Demetri,
Axel Le Cesne,
Sant P. Chawla,
Thomas Brodowicz,
Robert G. Maki,
Bruce A. Bach,
Dominic P. Smethurst,
Sarah Bray,
Yong-jiang Hei,
Jean-Yves Blay
et al.
|
Full-length article
(In Press Corrected Proof)
|
13 January 2012 |
|
Electroporation adopting trains of biphasic pulses enhances in vitro and in vivo the cytotoxic effect of doxorubicin on multidrug resistant colon adenocarcinoma cells (LoVo)
DOI: 10.1016/j.ejca.2011.11.031
Abstract: Few articles in the literature have focused on electroporation as a strategy to reverse multidrug resistance (MDR) of tumour cells and they are mostly limited to the improved efficacy of ble...
|
Stefania Meschini,
Maria Condello,
Pasquale Lista,
Bruno Vincenzi,
Alfonso Baldi,
Gennaro Citro,
Giuseppe Arancia,
Enrico P. Spugnini
et al.
|
Full-length article
(In Press Corrected Proof)
|
13 January 2012 |
|
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trial
DOI: 10.1016/j.ejca.2011.12.006
Abstract: Background: The phase III Sorafenib Asia–Pacific (AP) trial—conducted in China, Taiwan and South Korea – confirmed that sorafenib improves overall survival (OS) and is safe for patients with...
|
Ann-Lii Cheng,
Zhongzhen Guan,
Zhendong Chen,
Chao-Jung Tsao,
Shukui Qin,
Jun Suk Kim,
Tsai-Sheng Yang,
Won Young Tak,
Hongming Pan,
Shiying Yu,
Jianming Xu,
Fang Fang,
Jessie Zou,
Giuseppe Lentini,
Dimitris Voliotis,
Yoon-Koo Kang
et al.
|
Full-length article
(In Press Corrected Proof)
|
12 January 2012 |
|
Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses
DOI: 10.1016/j.ejca.2011.12.003
Abstract: Purpose: The combination of two tumour markers, CA125 and HE4, in the risk of ovarian malignancy assay (ROMA) has been shown to be successful in classifying patients into those who have a hi...
|
Toon Van Gorp,
Joan Veldman,
Ben Van Calster,
Isabelle Cadron,
Karin Leunen,
Frederic Amant,
Dirk Timmerman,
Ignace Vergote
et al.
|
Full-length article
(In Press Corrected Proof)
|
09 January 2012 |
|
Imaging apoptosis with positron emission tomography: ‘Bench to bedside’ development of the caspase-3/7 specific radiotracer [18F]ICMT-11
DOI: 10.1016/j.ejca.2011.11.033
Abstract: The capacity to evade apoptosis has been defined as one of the hallmarks of cancer and, thus, effective anti-cancer therapy often induces apoptosis. A biomarker for imaging apoptosis could a...
|
Quang-Dé Nguyen,
Amarnath Challapalli,
Graham Smith,
Robin Fortt,
Eric O. Aboagye
et al.
|
Full-length article
(In Press Corrected Proof)
|
09 January 2012 |
|
Epidemiology of glial and non-glial brain tumours in Europe
DOI: 10.1016/j.ejca.2011.12.013
Abstract: To the central nervous system (CNS) belong a heterogeneous group of glial and non glial rare cancers. The aim of the present study was to estimate the burden (incidence, prevalence, survival...
|
Emanuele Crocetti,
Annalisa Trama,
Charles Stiller,
Adele Caldarella,
Riccardo Soffietti,
Jana Jaal,
Damien C. Weber,
Umberto Ricardi,
Jerzy Slowinski,
Alba Brandes,
RARECARE working group
et al.
|
Full-length article
(In Press Corrected Proof)
|
09 January 2012 |
|
Tumour-derived IL-10 within tumour microenvironment represses the antitumour immunity of Socs1-silenced and sustained antigen expressing DCs
DOI: 10.1016/j.ejca.2011.12.009
Abstract: It has been shown that silencing of suppressor of cytokine signalling 1 (Socs1) or stably expressing transgenic protein Ags in antigen-presenting dentritic cells (DCs) strongly enhances anti...
|
Shuxia Song,
Yue Wang,
Junxia Wang,
Weiguang Lian,
Shufeng Liu,
Zhengzheng Zhang,
Fuying Liu,
Lin Wei
et al.
|
Full-length article
(In Press Corrected Proof)
|
09 January 2012 |
|
Apparent diffusion coefficient from magnetic resonance imaging as a biomarker in oncology drug development
DOI: 10.1016/j.ejca.2011.11.034
Abstract: Magnetic resonance imaging (MRI) can be made sensitive to diffusion of water molecules in biological tissues: this phenomenon can be quantitated to provide a biomarker, the apparent diffusio...
|
Ralph Sinkus,
Bernard E. Van Beers,
Valérie Vilgrain,
Nandita DeSouza,
John C. Waterton
et al.
|
Full-length article
(In Press Corrected Proof)
|
09 January 2012 |
|
Allergy-associated symptoms in relation to childhood non-Hodgkin’s as contrasted to Hodgkin’s lymphomas: A case–control study in Greece and meta-analysis
DOI: 10.1016/j.ejca.2011.12.010
Abstract: An increase of the prevalence of childhood allergic diseases and the incidence of childhood Hodgkin’s (HL) and non-Hodgkin’s lymphoma (NHL) were reported in the late 20th century. Among adul...
|
Stavroula K. Dikalioti,
Ellen T. Chang,
Nick Dessypris,
Charalampia Papadopoulou,
Nick Skenderis,
Apostolos Pourtsidis,
Maria Moschovi,
Sophia Polychronopoulou,
Fani Athanasiadou-Piperopoulou,
Vassiliki Sidi,
Maria Kalmanti,
Eleni Th. Petridou
et al.
|
Full-length article
(In Press Corrected Proof)
|
09 January 2012 |
|
Qualification of imaging biomarkers for oncology drug development
DOI: 10.1016/j.ejca.2011.11.037
Abstract: Although many imaging biomarkers have been described for cancer research, few are sufficiently robust, reliable and well-characterised to be used as routine tools in clinical cancer research...
|
John C. Waterton,
Liisa Pylkkanen
|
Full-length article
(In Press Corrected Proof)
|
09 January 2012 |
|
Mucinous adenocarcinomas: Poor prognosis in metastatic colorectal cancer
DOI: 10.1016/j.ejca.2011.12.004
Abstract: Purpose: Mucinous histology of metastatic colorectal cancer (CRC) has been associated with poor prognosis, however this has never been assessed in large well-defined study populations treate...
|
Leonie J.M. Mekenkamp,
Karin J. Heesterbeek,
Miriam Koopman,
Jolien Tol,
Steven Teerenstra,
Sabine Venderbosch,
Cornelis J.A. Punt,
Iris D. Nagtegaal
et al.
|
Full-length article
(In Press Corrected Proof)
|
06 January 2012 |
|
Fluorescence lifetime imaging of E-combretastatin uptake and distribution in live mammalian cells
DOI: 10.1016/j.ejca.2011.11.025
Abstract: To investigate within live mammalian cells the uptake and disposition of combretastatins, fluorescence lifetime imaging was used with two-photon excitation (2PE). Combretastatin A4 (CA4) and...
|
Roger H. Bisby,
Stanley W. Botchway,
John A. Hadfield,
Alan T. McGown,
Anthony W. Parker,
Kathrin M. Scherer
et al.
|
Full-length article
(In Press Corrected Proof)
|
03 January 2012 |
|
[18F]FLT: An imaging biomarker of tumour proliferation for assessment of tumour response to treatment
DOI: 10.1016/j.ejca.2011.11.035
Abstract: The paradigm of drug development is shifting towards early use of imaging biomarkers as surrogate end-points in clinical trials. Quantitative Imaging in Cancer: Connecting Cellular Processes...
|
Dmitry Soloviev,
David Lewis,
Davina Honess,
Eric Aboagye
|
Full-length article
(In Press Corrected Proof)
|
03 January 2012 |
|
CXCL5, a promoter of cell proliferation, migration and invasion, is a novel serum prognostic marker in patients with colorectal cancer
DOI: 10.1016/j.ejca.2011.11.032
Abstract: Purpose: Serum CXCL5 levels in patients with colorectal cancer (CRC) were assessed to evaluate correlation with clinicopathologic features and prognosis. The effects of CXCL5 on CRC cells we...
|
Mikio Kawamura,
Yuji Toiyama,
Kouji Tanaka,
Susumu Saigusa,
Yoshinaga Okugawa,
Junichiro Hiro,
Keiichi Uchida,
Yasuhiko Mohri,
Yasuhiro Inoue,
Masato Kusunoki
et al.
|
Full-length article
(In Press Corrected Proof)
|
26 December 2011 |
|
Sexuality and body image in long-term survivors of testicular cancer
DOI: 10.1016/j.ejca.2011.11.029
Abstract: Objective: This study explores sexual function and the influence of different treatment modalities on sexual function and body image among long-term survivors of testicular cancer (TCSs). Me...
|
P. Rossen,
A.F. Pedersen,
R. Zachariae,
H. von der Maase
|
Full-length article
(In Press Corrected Proof)
|
26 December 2011 |
|
Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b
DOI: 10.1016/j.ejca.2011.11.019
Abstract: Purpose: To compare health-related quality of life (HRQoL) and side-effects in patients with high-risk melanoma participating in a randomised phase III trial of adjuvant interferon alfa-2b (...
|
Y. Brandberg,
S. Aamdal,
L. Bastholt,
M. Hernberg,
U. Stierner,
H. von der Maase,
J. Hansson
et al.
|
Full-length article
(In Press Corrected Proof)
|
26 December 2011 |
|
Safety of bevacizumab in metastatic breast cancer patients undergoing surgery
DOI: 10.1016/j.ejca.2011.11.021
Abstract: Background: Evaluate the safety of surgery in relation to bevacizumab in the first-line treatment of metastatic breast cancer (mBC) in two international trials. Patients and methods: The inc...
|
Javier Cortés,
Mireia Caralt,
Suzette Delaloge,
Hernan Cortes-Funes,
Jean-Yves Pierga,
Kathleen I. Pritchard,
David T. Bollag,
David W. Miles
et al.
|
Full-length article
(In Press Corrected Proof)
|
26 December 2011 |
|
Conditional survival of patients with urothelial carcinoma of the urinary bladder treated with radical cystectomy
DOI: 10.1016/j.ejca.2011.11.024
Abstract: Aim of study: To examine the impact of survival probability according to duration of survivorship following radical cystectomy (RC) in patients diagnosed with urothelial carcinoma of the uri...
|
Maxine Sun,
Firas Abdollah,
Marco Bianchi,
Quoc-Dien Trinh,
Shahrokh F. Shariat,
Claudio Jeldres,
Zhe Tian,
Jens Hansen,
Alberto Briganti,
Markus Graefen,
Francesco Montorsi,
Paul Perrotte,
Pierre I. Karakiewicz
et al.
|
Full-length article
(In Press Corrected Proof)
|
23 December 2011 |
|
Socio-economic implications of cancer survivorship: Results from the PROFILES registry
DOI: 10.1016/j.ejca.2011.11.030
Abstract: Introduction: The goal of this large population-based study was to examine the socio-economic implications of cancer survivorship. Methods: Individuals alive and diagnosed with colorectal ca...
|
Floortje Mols,
Melissa S.Y. Thong,
Pauline Vissers,
Tamar Nijsten,
Lonneke V. van de Poll-Franse
et al.
|
Full-length article
(In Press Corrected Proof)
|
23 December 2011 |
|
MicroRNA-610 inhibits the migration and invasion of gastric cancer cells by suppressing the expression of vasodilator-stimulated phosphoprotein
DOI: 10.1016/j.ejca.2011.11.026
Abstract: Vasodilator-stimulated phosphoprotein (VASP) has been implicated in the establishment of cancerous phenotypes. However, the role of VASP in gastric cancer progression and metastasis remains ...
|
Jing Wang,
Jingwei Zhang,
Junzhu Wu,
Daji Luo,
Ke Su,
Wentao Shi,
Jian Liu,
Yihao Tian,
Lei Wei
et al.
|
Full-length article
(In Press Corrected Proof)
|
22 December 2011 |
|
Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data
DOI: 10.1016/j.ejca.2011.11.014
Abstract: Background: The PORTEC-2 trial showed efficacy and reduced side-effects of vaginal brachytherapy (VBT) compared with external beam pelvic radiotherapy (EBRT) for patients with high-intermedi...
|
Remi A. Nout,
Hein Putter,
Ina M. Jürgenliemk-Schulz,
Jan J. Jobsen,
Ludy C.H.W. Lutgens,
Elzbieta M. van der Steen-Banasik,
Jan Willem M. Mens,
Annerie Slot,
Marika C. Stenfert Kroese,
Hans W. Nijman,
Lonneke V. van de Poll-Franse,
Carien L. Creutzberg
et al.
|
Full-length article
(In Press Corrected Proof)
|
19 December 2011 |
|
Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine
DOI: 10.1016/j.ejca.2011.11.018
Abstract: Background: Vinflunine (VFL) has been approved in the European Union for second-line treatment of advanced transitional cell carcinoma of the urothelial tract (TCCU) in patients who progress...
|
Katherine M. Krajewski,
Ronan Fougeray,
Joaquim Bellmunt,
Francesc Pons,
Fabio A.B. Schutz,
Jonathan E. Rosenberg,
Yacine Salhi,
Toni K. Choueiri
et al.
|
Full-length article
(In Press Corrected Proof)
|
16 December 2011 |
|
Offering self-sampling for human papillomavirus testing to non-attendees of the cervical screening programme: Characteristics of the responders
DOI: 10.1016/j.ejca.2011.11.022
Abstract: Background: Self-sampling for high-risk human papillomavirus (hrHPV) testing is accepted by up to 30% of non-attendees to the regular cervical screening programme. Here, the yield of cervica...
|
Murat Gök,
Daniëlle A.M. Heideman,
Folkert J. van Kemenade,
Anton L.M. de Vries,
Johannes Berkhof,
Lawrence Rozendaal,
Jeroen A.M. Beliën,
Lucy Overbeek,
Milena Babović,
Peter J.F. Snijders,
Chris J.L.M. Meijer
et al.
|
Full-length article
(In Press Corrected Proof)
|
15 December 2011 |
|
A multi-institutional phase II trial of consolidation S-1 after concurrent chemoradiotherapy with cisplatin and vinorelbine for locally advanced non-small cell lung cancer
DOI: 10.1016/j.ejca.2011.11.020
Abstract: Aim: To evaluate the efficacy and feasibility of the consolidation therapy of the oral fluoropyrimidine agent S-1 after concurrent chemoradiotherapy for unresectable stage III non-small cell...
|
Tomoya Kawaguchi,
Minoru Takada,
Masahiko Ando,
Kyoichi Okishio,
Shinji Atagi,
Yuka Fujita,
Yoshio Tomizawa,
Kenji Hayashihara,
Yoshio Okano,
Fumiaki Takahashi,
Ryusei Saito,
Akihide Matsumura,
Atsuhisa Tamura
et al.
|
Full-length article
(In Press Corrected Proof)
|
15 December 2011 |
|
Venous thromboembolism (VTE) in patients with advanced gastric cancer: An Asian experience
DOI: 10.1016/j.ejca.2011.11.016
Abstract: Background: The incidence and prognostic impact of venous thromboembolism (VTE) in patients with advanced gastric cancer (AGC) have not been determined. We therefore investigated the inciden...
|
Myoung Joo Kang,
Baek-Yeol Ryoo,
Min-Hee Ryu,
Dong-Hoe Koo,
Heung Moon Chang,
Jae-Lyun Lee,
Tae Won Kim,
Yoon-Koo Kang
et al.
|
Full-length article
(In Press Corrected Proof)
|
14 December 2011 |
|
Pitfalls and limitations of a single-centre, retrospectively derived prognostic score for Phase I oncology trial participants – Reply to Fussenich et al.: A new, simple and objective prognostic score for Phase I cancer patients
DOI: 10.1016/j.ejca.2011.11.004
We read with interest the derivation of a new prognostic scoring system by Fussenich et al. which adds to efforts by several groups aiming to provide objective risk stratification and optimise patient...
|
David Olmos,
Joo Ern Ang,
Carlos Gomez-Roca,
Rafael Morales-Barrera,
Annelie J. Vulink,
Christophe Massard,
Stan Kaye,
on behalf of the EDDN
et al.
|
Correspondence
(In Press Corrected Proof)
|
12 December 2011 |
|
Incidence, prevalence and survival of patients with rare epithelial digestive cancers diagnosed in Europe in 1995–2002
DOI: 10.1016/j.ejca.2011.10.038
Abstract: Background and aims: Little is known about the epidemiology of rare epithelial digestive cancers. The aim of this study was to report on their incidence, prevalence and survival across Europ...
|
J. Faivre,
A. Trama,
R. De Angelis,
M. Elferink,
S. Siesling,
R. Audisio,
J.F. Bosset,
A. Cervantes,
C. Lepage,
The RARECARE Working Group
et al.
|
Full-length article
(In Press Corrected Proof)
|
12 December 2011 |
|
Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent
DOI: 10.1016/j.ejca.2011.11.009
Abstract: Introduction: Malignant pleural mesothelioma (MPM) is a rapidly fatal malignancy that is increasing in incidence. The caspase 8 inhibitor FLIP is an anti-apoptotic protein over-expressed in ...
|
Jane L. Hurwitz,
Izabela Stasik,
Emma M. Kerr,
Caitriona Holohan,
Kelly M. Redmond,
Kirsty M. McLaughlin,
Sara Busacca,
Dario Barbone,
V. Courtney Broaddus,
Steven G. Gray,
Ken J. O’Byrne,
Patrick G. Johnston,
Dean A. Fennell,
Daniel B. Longley
et al.
|
Full-length article
(In Press Corrected Proof)
|
12 December 2011 |
|
Local therapy is critical in localised pelvic rhabdomyosarcoma: Experience of the International Society of Pediatric Oncology Malignant Mesenchymal Tumor (SIOP-MMT) committee
DOI: 10.1016/j.ejca.2011.11.011
Abstract: Background: Localised pelvic rhabdomyosarcomas (pRMS) are rare tumours with a poorer prognosis than the majority of RMS. This study analysed patient outcome according to the type of local th...
|
Yves Réguerre,
Hélène Martelli,
Annie Rey,
Timothy Rogers,
Mark Gaze,
Myriam Weyl Ben Arush,
Christine Devalck,
Odile Oberlin,
Michael Stevens,
Daniel Orbach
et al.
|
Full-length article
(In Press Corrected Proof)
|
09 December 2011 |
|
A long duration of the prediagnostic symptomatic interval is not associated with an unfavourable prognosis in childhood medulloblastoma
DOI: 10.1016/j.ejca.2011.11.012
Abstract: Background: Due to the lacking specificity of symptoms making a correct diagnosis can be a challenge in children with medulloblastoma. This can lead to prediagnostic symptomatic intervals (P...
|
Nicolas U. Gerber,
Katja von Hoff,
André O. von Bueren,
Wiebke Treulieb,
Frank Deinlein,
Martin Benesch,
Isabella Zwiener,
Niels Soerensen,
Monika Warmuth-Metz,
Torsten Pietsch,
Uwe Mittler,
Joachim Kuehl,
Rolf-Dieter Kortmann,
Michael A. Grotzer,
Stefan Rutkowski
et al.
|
Full-length article
(In Press Corrected Proof)
|
09 December 2011 |